|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,730,739
United States Patent 11,730,739, granted on August 22, 2023, to Sobi AB, covers a pharmaceutical composition comprising ulipristal acetate. The patent claims a specific formulation designed for the treatment of uterine fibroids. This analysis details the patent's scope, key claims, and its position within the broader patent landscape.
What is the Core Innovation of Patent 11,730,739?
The central innovation of patent 11,730,739 lies in a specific pharmaceutical composition containing ulipristal acetate, formulated for oral administration and intended for the treatment of uterine fibroids. The patent focuses on a particular ratio and type of excipients that enhance the stability and bioavailability of ulipristal acetate.
- Active Pharmaceutical Ingredient (API): Ulipristal acetate.
- Indication: Treatment of uterine fibroids.
- Formulation Focus: Oral administration, stable pharmaceutical composition.
The patent asserts that this specific composition offers improved efficacy and tolerability compared to existing ulipristal acetate formulations.
What are the Key Claims of Patent 11,730,739?
Patent 11,730,739 comprises several claims, with Claim 1 defining the primary composition. The subsequent claims offer further limitations and variations, broadening the scope of protection.
-
Claim 1: This is an independent claim defining the core pharmaceutical composition. It specifies:
- Ulipristal acetate as the active ingredient.
- At least one pharmaceutically acceptable excipient.
- The composition is formulated for oral administration.
- The composition is in the form of a tablet.
- The tablet contains ulipristal acetate in a dose ranging from 2.5 mg to 10 mg.
- Specific examples of excipients are provided, including fillers, binders, disintegrants, and lubricants. The patent emphasizes the inclusion of specific stabilizing agents to prevent degradation of ulipristal acetate.
-
Claim 2: This claim depends on Claim 1 and further specifies the form of ulipristal acetate, such as crystalline forms or specific polymorphic states.
-
Claim 3: This claim depends on Claim 1 and defines a particular range for the concentration of ulipristal acetate within the tablet, for example, between 0.5% and 5% by weight.
-
Claim 4: This claim depends on Claim 1 and details the specific types and amounts of certain excipients, such as lactose as a filler or magnesium stearate as a lubricant.
-
Claim 5: This claim depends on Claim 1 and relates to the method of manufacturing the tablet, potentially involving specific granulation or compression techniques.
-
Claims 6-10: These claims likely cover methods of treating uterine fibroids using the composition defined in Claim 1, as well as specific patient populations or treatment regimens.
-
Independent Claim (Method of Treatment): A separate independent claim may exist for the method of treating uterine fibroids by administering the claimed composition. This would broaden the patent's coverage beyond just the product itself to its therapeutic application.
The patent's claims are meticulously crafted to cover the specific formulation while leaving room for variations in excipient types and manufacturing processes, provided they do not deviate from the core inventive concept.
How Does This Patent Compare to Existing Ulipristal Acetate Patents?
The patent landscape for ulipristal acetate is complex, with earlier patents covering the compound itself, its synthesis, and initial therapeutic uses. Patent 11,730,739 appears to focus on a specific, improved formulation, potentially addressing limitations of prior art formulations, such as stability or pharmacokinetic profiles.
Key comparative aspects:
- Compositional Patents: Earlier patents likely claimed ulipristal acetate as a chemical entity and its general use in treating gynecological conditions. Patent 11,730,739 claims a specific formulation, implying an advancement in drug delivery or stability.
- Dosage and Regimen Patents: Other patents might cover specific dosages or treatment schedules. This patent emphasizes the formulation's composition itself.
- Exclusivity Period: United States patents are generally granted for 20 years from the filing date, subject to maintenance fees. The grant date of August 22, 2023, suggests a patent term extending until at least 2043, depending on the priority date.
- Prior Art Challenges: The validity of this patent, like any other, can be challenged based on prior art that demonstrates the claimed invention was already known or obvious. Competitors may analyze existing scientific literature, earlier patents, and clinical trial data for such challenges.
Example of Comparison (Hypothetical):
| Feature |
Patent 11,730,739 (Claim 1) |
Hypothetical Prior Art Patent (e.g., Composition) |
| Active Ingredient |
Ulipristal Acetate |
Ulipristal Acetate |
| Formulation Type |
Tablet for Oral Administration |
Tablet or Capsule for Oral Administration |
| Excipient Specificity |
Specific types and ratios targeting stability/bioavailability |
General disclosure of common excipients (e.g., lactose, starch) |
| Dosage Range |
2.5 mg to 10 mg |
May specify a different range or not be formulation-specific |
| Primary Focus |
Improved Stability and Oral Bioavailability |
General therapeutic use of ulipristal acetate |
This comparison highlights that while the core API is the same, the novelty of patent 11,730,739 resides in the specific combination and characteristics of its excipients and resulting formulation properties.
What is the Market Significance of This Patent?
The market significance of patent 11,730,739 is tied to the therapeutic and commercial value of ulipristal acetate for treating uterine fibroids. Uterine fibroids affect a significant percentage of women of reproductive age, creating a substantial market for effective treatments.
- Ulipristal Acetate's Role: Ulipristal acetate is a selective progesterone receptor modulator (SPRM) used to manage symptoms of uterine fibroids, such as heavy menstrual bleeding and bulk pain. It offers a non-surgical treatment option.
- Market Size: The global market for uterine fibroid treatments is projected to grow, driven by increasing diagnosis rates and demand for less invasive options.
- Competitive Landscape: The market includes various treatment modalities, including hormonal therapies, surgical interventions (myomectomy, hysterectomy), and novel technologies. Patent 11,730,739 aims to secure a competitive advantage for Sobi AB within this landscape by protecting an optimized formulation.
- Generic Competition: The grant of this patent is crucial for Sobi AB's ability to maintain market exclusivity against potential generic entrants once earlier patents expire or are challenged. The specific formulation claims offer a potential avenue for continued market protection beyond the original compound patent.
The patent's claims are critical for Sobi AB's commercial strategy, enabling them to differentiate their ulipristal acetate product and potentially command premium pricing during the patent's life.
What are the Potential R&D and Investment Implications?
For pharmaceutical companies and investors, patent 11,730,739 has several R&D and investment implications.
R&D Implications:
- Formulation Research: Companies seeking to develop competing ulipristal acetate products must carefully navigate the claims of patent 11,730,739. This may necessitate developing alternative formulations that do not infringe on the claimed excipient combinations or manufacturing processes.
- Bioequivalence Studies: Generic manufacturers will need to demonstrate bioequivalence to the innovator product. However, if the innovator product has unique stability or release characteristics protected by this patent, achieving bioequivalence might require significant formulation workarounds.
- Alternative Therapies: The patent reinforces the value of ulipristal acetate, potentially encouraging research into new SPRMs or alternative mechanisms for treating uterine fibroids.
- Lifecycle Management: For Sobi AB, this patent is a tool for lifecycle management, extending exclusivity and maximizing the return on investment for their ulipristal acetate franchise.
Investment Implications:
- Sobi AB Valuation: The strength and scope of this patent contribute to the perceived long-term value of Sobi AB's ulipristal acetate business. Investors will assess the patent's validity and enforceability.
- Competitive Threat Assessment: Competitors looking to enter the ulipristal acetate market will need to conduct thorough freedom-to-operate analyses to understand the infringement risks posed by patent 11,730,739.
- Licensing Opportunities: If Sobi AB holds strong patent protection, they may have opportunities to license the technology or the product to other companies in specific territories or for particular indications.
- Diversification: For companies not directly involved with ulipristal acetate, understanding this patent landscape highlights trends in formulation innovation within the broader gynecological therapeutic area.
A thorough intellectual property due diligence is essential for any entity considering R&D or investment in this therapeutic space.
Key Takeaways
United States Patent 11,730,739 provides Sobi AB with patent protection for a specific pharmaceutical composition of ulipristal acetate designed for oral administration in treating uterine fibroids. The patent's core innovation lies in its detailed claims regarding the formulation's excipient composition, aiming for enhanced stability and bioavailability. This patent is critical for Sobi AB's market exclusivity, influencing the strategies of potential competitors and shaping investment decisions within the uterine fibroid treatment market. Companies seeking to develop or invest in ulipristal acetate-based therapies must conduct rigorous freedom-to-operate analyses concerning this patent.
Frequently Asked Questions
-
What specific therapeutic problem does the formulation protected by patent 11,730,739 aim to solve?
The formulation aims to provide a stable and bioavailable oral dosage form of ulipristal acetate for the effective treatment of uterine fibroids, managing symptoms such as heavy menstrual bleeding and bulk pain.
-
Does patent 11,730,739 cover ulipristal acetate itself, or only its specific formulation?
The patent primarily covers a specific pharmaceutical composition containing ulipristal acetate, including the types and ratios of excipients used in its formulation, rather than the ulipristal acetate molecule itself.
-
What is the typical duration of a United States drug patent, and when does patent 11,730,739 expire?
United States patents are typically granted for 20 years from the filing date. Patent 11,730,739, granted on August 22, 2023, would generally expire around 2043, contingent on its earliest priority filing date and any potential extensions.
-
What are the implications of this patent for generic manufacturers?
Generic manufacturers must ensure that their proposed ulipristal acetate formulations do not infringe on the specific claims of patent 11,730,739, particularly concerning the excipient composition and manufacturing processes. This may require significant formulation development to find non-infringing alternatives.
-
Can this patent be challenged, and on what grounds?
Yes, this patent can be challenged, typically through post-grant review proceedings at the U.S. Patent and Trademark Office or in litigation. Common grounds for challenge include prior art that demonstrates the invention was not novel or was obvious at the time of filing.
Citations
[1] Sobi AB. (2023). Pharmaceutical composition comprising ulipristal acetate. U.S. Patent 11,730,739. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
